Conservation and Evolution of Antigenic Determinants of SARS-CoV-2: An Insight for Immune Escape and Vaccine Design

被引:8
作者
Jaiswal, Varun [1 ]
Lee, Hae-Jeung [1 ,2 ,3 ]
机构
[1] Gachon Univ, Coll BioNano Technol, Dept Food & Nutr, Seongnam, South Korea
[2] Gachon Univ, Inst Aging & Clin Nutr Res, Seongnam, South Korea
[3] Gachon Univ, Dept Hlth Sci & Technol, GAIHST, Incheon, South Korea
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
COVID-19; SARS-CoV-2; evolution; immunity; vaccine; mutation; B-cell epitopes; T-cell epitopes; POINT MUTATION; EPITOPE;
D O I
10.3389/fimmu.2022.832106
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Coronavirus disease 2019 (COVID-19) is the most devastating pandemic of the century, which is still far from over. The remarkable success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is the working hope, but the evolving variants are the huge concern that can turn the tide. Potential immune escape mutations (PIEMs) in the past and circulating variants were not studied at large scale (all available data). Hence, the conservation of antigenic determinants (epitopes) was analyzed in all available sequences of SARS-CoV-2 according to time (months), proteins, hosts, and variants. Numerous highly conserved B- and T-cell epitopes were identified in 24 proteins of SARS-CoV-2. A decrease in the conservation of epitopes with time was observed in almost all proteins, which was more rapid in neutralizing epitopes. Delta variant still has the highest PIEM in the circulating strains, which pose threat to the effectiveness of current vaccines. The inclusion of identified, highly conserved, and important epitopes in subunit vaccines can increase vaccine effectiveness against evolving variants. Trends in the conservation of epitopes in different proteins, hosts, and variants with time may also help to inspire the counter measure against the current pandemic.
引用
收藏
页数:8
相关论文
共 35 条
  • [21] A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope
    Keck, Zhen-Yong
    Olson, Oakley
    Gal-Tanamy, Meital
    Xia, Jinming
    Patel, Arvind H.
    Dreux, Marlene
    Cosset, Francois-Loic
    Lemon, Stanley M.
    Foung, Steven K. H.
    [J]. JOURNAL OF VIROLOGY, 2008, 82 (12) : 6067 - 6072
  • [22] Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals
    Kustin, Talia
    Harel, Noam
    Finkel, Uriah
    Perchik, Shay
    Harari, Sheri
    Tahor, Maayan
    Caspi, Itamar
    Levy, Rachel
    Leshchinsky, Michael
    Ken Dror, Shifra
    Bergerzon, Galit
    Gadban, Hala
    Gadban, Faten
    Eliassian, Eti
    Shimron, Orit
    Saleh, Loulou
    Ben-Zvi, Haim
    Keren Taraday, Elena
    Amichay, Doron
    Ben-Dor, Anat
    Sagas, Dana
    Strauss, Merav
    Shemer Avni, Yonat
    Huppert, Amit
    Kepten, Eldad
    Balicer, Ran D.
    Netzer, Doron
    Ben-Shachar, Shay
    Stern, Adi
    [J]. NATURE MEDICINE, 2021, 27 (08) : 1379 - +
  • [23] Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
    Lange, Bettina
    Gerigk, Marlis
    Tenenbaum, Tobias
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (12) : 1145 - 1146
  • [24] PDBsum extras: SARS-CoV-2 and AlphaFold models
    Laskowski, Roman A.
    Thornton, Janet M.
    [J]. PROTEIN SCIENCE, 2022, 31 (01) : 283 - 289
  • [25] Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
    Levin, Einav G.
    Lustig, Yaniv
    Cohen, Carmit
    Fluss, Ronen
    Indenbaum, Victoria
    Amit, Sharon
    Doolman, Ram
    Asraf, Keren
    Mendelson, Ella
    Ziv, Arnona
    Rubin, Carmit
    Freedman, Laurence
    Kreiss, Yitshak
    Regev-Yochay, Gili
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (24) : E84 - E84
  • [26] Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
    Lou, Fuxing
    Li, Maochen
    Pang, Zehan
    Jiang, Lin
    Guan, Lin
    Tian, Lili
    Hu, Jiaming
    Fan, Junfen
    Fan, Huahao
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [27] A call to cellular and humoral arms
    McMurry, Julie A.
    Johansson, Bert E.
    De Groot, Anne S.
    [J]. HUMAN VACCINES, 2008, 4 (02): : 148 - 157
  • [28] Antibodies and Vaccines Target RBD of SARS-CoV-2
    Min, Long
    Sun, Qiu
    [J]. FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
  • [29] Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
    Mizrahi, Barak
    Lotan, Roni
    Kalkstein, Nir
    Peretz, Asaf
    Perez, Galit
    Ben-Tov, Amir
    Chodick, Gabriel
    Gazit, Sivan
    Patalon, Tal
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [30] Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
    Pouwels, Koen B.
    Pritchard, Emma
    Matthews, Philippa C.
    Stoesser, Nicole
    Eyre, David W.
    Vihta, Karina-Doris
    House, Thomas
    Hay, Jodie
    Bell, John, I
    Newton, John N.
    Farrar, Jeremy
    Crook, Derrick
    Cook, Duncan
    Rourke, Emma
    Studley, Ruth
    Peto, Tim E. A.
    Diamond, Ian
    Walker, A. Sarah
    [J]. NATURE MEDICINE, 2021, 27 (12) : 2127 - +